Evidence map›Paper›PMID 32050707›Full record

ArticleBiology2020

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.

Daniil Zaytsev, Larisa Girshova, Vladimir Ivanov, Irina Budaeva, Dmitri Motorin, Renat Badaev, Julia Mirolubova, Evgeni Grobovenko, Tamara Chitanava, Ekaterina Zaykova and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Daniil ZaytsevAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Larisa GirshovaAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Vladimir IvanovAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Irina BudaevaAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Dmitri MotorinAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Renat BadaevAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Julia MirolubovaAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Evgeni GrobovenkoAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Tamara ChitanavaAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Ekaterina ZaykovaAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Julia AlexeevaAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Andrey ZaritskeyAlmazov National Medical Research Centre, 2 Akkuratova street, 197341 St. Petersburg, Russia.
Federal Almazov North-West Medical Research Centre · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never been reported. This study aimed to demonstrate the efficacy and rapid response of Gemtuzumab ozogamicin in refractory acute myeloid leukemia (AML) patients with pulmonary and kidney failure and poor performance status. Three refractory AML patients, with organ dysfunction, are described. One patient was pre-treated with intensive chemotherapy, and two other patients progressed during Azacitidine treatment. Two patients had respiratory failure grade 2 and one patient suffered from acute kidney insufficiency. Two patients were highly febrile with an elevated С-Reactive Protein (CRP) level. The WHO performance status of three was measured in all patients. Gemtuzumab ozogamicin administration was performed in three patients, followed by a further switch to Gemtuzumab ozogamicin + Azacitidine or "7+3" treatment.

resultsGemtuzumab ozogamicin administration resulted in abrupt fever cessation in two febrile patients simultaneously with a rapid decrease in CRP level and fast resolution of respiratory failure. Recovery of kidney function was noticed rapidly in patients with renal insufficiency. The WHO performance status was elevated in all three patients. No adverse grade II-III effects were noticed. Further treatment made two patients eligible for intensive chemotherapy, one patient underwent allogeneic stem cell transplantation, and the patient with kidney failure obtained complete remission.

conclusionsGemtuzumab ozogamicin therapy appeared to be safe and highly efficacious in relapsed/refractory AML patients with organ dysfunction, like pulmonary or renal failure and poor performance status, and may contribute to rapid recovery from organ failures.

Indexed as

acute myeloid leukemiagemtuzumab ozogamicinkidney failureorgan dysfunctionrespiratory failure

Identifiers

PMID32050707
PMCPMC7167863
OpenAlexW3004964434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.